Pfizer has announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, due to drug-induced liver injury. Danuglipron (PF-06882961) was being investigated for chronic weight management. The company’s dose-optimisation studies of once-daily formulations of danuglipron met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!